Nasus Pharma Ltd
NSRXNYSEHealthcare · Pharmaceutical Preparations · L3 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Enrolling By Invitationreadout ~2026-03Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis
- Phase 2/3Enrolling By Invitationreadout ~2026-06-12FMXIN002 in Patients at Risk of Anaphylaxis
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Balyasny Asset Management L.P.Passive (13G)May 15, 2026
- Funicular Funds, LpPassive (13G)Apr 7, 2026
- Hershman RonniePassive (13G)Nov 13, 2025
- Megiddo DaliaPassive (13G)Nov 12, 2025
- Gilboa UdiPassive (13G)Nov 10, 2025
- Capital Point Ltd.Passive (13G)Aug 20, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 155,032 | 2.1 | +39.6% |
| Apr 30, 2026 | 111,022 | 1.0 | +71.0% |
| Apr 15, 2026 | 64,912 | 2.2 | -34.6% |
| Mar 31, 2026 | 99,202 | 1.0 | +771.7% |
| Mar 13, 2026 | 11,380 | 2.7 | +28.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.